Corporate presentation January 2013. What we do In depth technical expertise.

Slides:

Advertisements

Similar presentations

NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI) NEWMEDS Novel MEthods.

Advertisements

Technology Commercialisation System Richard Linley Associate Consultant.

What does a start-up company need from a Technology Transfer Unit? November 2007 Eporgen Venture S.p.A. Via Ribes, Colleretto Giacosa (TO) Italy.

Founded in 1998 Private not-for profit Oklahoma Corp. Offices in Oklahoma City and Tulsa Staff of 12.

A Case study of Biotechnology: - How to use Biotechnology for Economic Development Theme 3: IP Financing in the Field of Patents By Iain C Shirlaw Information.

Advancing technology and science companies. The Neem Tree is fast-growing and can thrive even in difficult drought-like conditions. Like the rapidly growing.

Contents Background and Introduction What is Private Equity?

Driving Innovation Concept to Commercialisation A strategy for business innovation, Zahid Latif Head of Healthcare Mark Glover 12 th January.

Funding for Innovation Sue Dunkerton, HealthTech and Medicines KTN 11 December 2012.

Chapter 14 Venture Capital Chapter 14 Entrepreneurial Finance, Smith and Kiholm Smith Venture Capital.

Towards the Global Markets Merja Heikela Senior Consultant, Finpro UK-Benelux.

Enterprise Ireland – Accelerating the growth of Irish companies in world markets Martin Corry 2009.

Global Software II Introduction Paving the Way to the US Market For Finnish Software Companies Copyright Global Software II 2002.

UW TechTransfer LaunchPad Initiative: A Resource for Startups December 4, 2008 Jim Roberts Business Development Officer UW TechTransfer.

January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.

AusIndustry Martin Cebis AusIndustry – Entrepreneur Development Facilitator.

Partnerships & Alliances Molecular Diagnostics Prof. K. K. Jain MD, FRACS, FFPM CEO, Jain PharmaBiotech Blaesiring 7, 4057 Basel, Switzerland Colloquim.

1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical development Phase I Phase II Phase III Product.

1 Presentation title - edit in the Master slide 1 Current Investment Opportunities Professor Rory Shaw, Medical Director, Healthcare UK, UKTI.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

Presentation to Thursday 13 th October axiom-e’s view All organisations need to have: a clear and realistic strategy, the financial resources,

”We aim to be the preferred life sciences investment company in Northern Europe…” “We have the people, the differentiation, the mind-set, and the structure.

September 5, 2013 Growing Missouri’s Economy Through Innovation and Entrepreneurship.

Leanna Davies Xénos the Wales Business Angel Network and Finance Wales.

FOOTPRINTS Organisations are continuously looking for Business, Partners, Alliances and Talented People Organisations are continuously looking for Opportunities.

May 29, Missouri Technology Corporation  Public-private partnership created by the Missouri General Assembly to lead efforts to promote entrepreneurship.

Page 1 New Models for Commercialization Federal Partners in Technology Transfer June 18, 2009 A presentation by: Tom Corr Chief Executive Officer Accelerator.

Overview & Industry Partnership Opportunities ©2012 Larta Institute

Integrating Innovation

Strategic Innovation Management Prof. Marc Gruber January 27 th, 2011.

The MBA DIVE Discovery, Innovation, and Ventures Enterprise The mission of the MBA DIVE is to endow students with professional knowledge and skills relevant.

Intellectual Property Rights Margaret Lawlor Business Development Manager Faculty of Medical Sciences 3rd October 2013 copyright©NewcastleUniversity 2013.

Life Science Venture Capital 11th Annual NIH SBIR/STTR Conference July 1, 2009 Randy H. Weiss, Ph.D. Partner, Triathlon Medical Ventures.

IPic 2012: Enterprise Name. Product Offering the problem and your solution.

11-1 Copyright © 2010 Pearson Education, Inc. publishing as Prentice Hall Part IV: Start-up Financial Strategy Chapter 11: Funding the Technology Start-up.

From Start Up to Scale Up: Financing For Sustainable Growth presented by Soo Boon KOH Managing Partner 31 st October 2013.

Hampton Consulting Ltd. Entrepreneurship & Venture Capital (VC) Investment A Risky Business?

HealthStart India Mr. Pradeep K. Jaisingh Chairman & Founder Enabling Healthcare Entrepreneurship.

Venture Investment Bank for Early Stage Technology Companies We Invest Through: –Angel & Institutional Investor Members –Capital Managed Internally NASD\Broker.

Growth Through Creativity and Science Growth through creativity and Science.

China Healthcare Consulting Inc. Creating Value for Our Clients Boston Healthcare Associates, Inc. 75 Federal Street, 9 th Floor.

An introduction to The University of Auckland’s Knowledge Transfer Company Dr Peter Lee, CEO.

ONTARIO CENTRES OF EXCELLENCE Briefing for the York Boot Camp July 19, 2012.

University Licensing Dominique Kleyn 27 th June 2003.

Building the Best Team that Delivers and that Investors Love TEAMWORK MAKES THE DREAM WORK:

Life Sciences in Scotland An Opportunity. Life Sciences Industry – Overview Scottish Life Sciences Industry – Vision and Strategy Scottish Enterprise.

TECHNOPOLIS OYJ Access to Customers, Capital and Partners Development Services.

1 Extending the Wisconsin Idea UW Funding Opportunities for Technologies with Promising Potential.

Corporate presentation January What we do In depth technical expertise.

Innovating Health Baltic Sea Region joins the forces Baltic Sea Parliamentary Conference, Pärnu, Aug 2013 Björn Söderberg, Külle Tärnov Accelerace Life.

1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.

1 Communicating with Venture Capitalists to Fund Your Research Raising Venture Capita l Michael Jirousek, Ph.D. Senior Advisor, Innovation Support Center.

Developing and Broadening Specialists in Research & Development

Financing Start Up & Growth Aspirational Companies

Open KPN Marie-José van den Boomgaard

Atlantic Bridge Dr Helen McBreen, INVESTMENT DIRECTOR

…. the Angel Perspective

Dr. Siegfried Bialojan Background Skills Professional experience

Executive Summary Regenerator Genetics, Inc is a genetic engineering company that intends to research, design, patent and market synthetic tissue samples.

BDC Good day everyone, My name is Mark Tanner and I am an Account Manager at the Business Development Bank of Canada, known as BDC. I am delighted to give.

Global Nanotechnology Business Incubator

Gestora brasileiro focada exclusivamente na área da saúde.

Present By:- Company Name: Global Market Forecastes Tel: / Web:

Finland, a Global Testbed for Personalized Cancer Research?

MTECH Technology Entrepreneurship Activities

M.D. – New Business and Partnerships

Gwyn Tudor Forum Manager - MediWales

Proposal Presentation to the

Expert Speak: How Pharma Companies Can Grow Their Business?

Strategic Merger Capital Raising Canada

Presentation transcript:

Corporate presentation January 2013

What we do

In depth technical expertise

Ithaka Track Record >190 assignments completed for >90 clients Worked with >25 universities on technology commercialisation 9 university spin-outs created and financed >£30 million funding for clients o Venture capital, corporate deals and grants Technical, commercial & IP evaluations undertaken for >30 organisations Due diligence conducted for 9 investment funds Unrivalled network of contacts

Ithaka Team Paul Rodgers Founder & MD, experienced biotech entrepreneur, biomarkers & personalised medicine AxisJohn Adair Biopharmaceutical R&D (Axis Genetics, Scotgen, Celltech, Searle) Richard Cumming Life science product development & marketing (Amersham, GE Healthcare) Bill Primrose Drug discovery & development (PanTherix, SioKem etc.) Mark Treherne Drug discovery & development (Senexis, Cyclofluidic, BioFocus, Pfizer etc.) Paula Wittels Medical devices & diagnostics (Pfizer, Quintiles etc.)

Ithaka: University Clients

Ithaka: Corporate Clients creating a new cancer therapy

Typical Assignments Business creation & sourcing finance  Psynova Neurotech & Smart Holograms Technical, commercial and market evaluation  Newcastle University: biofilm prevention  Manchester University: novel medical implant device  Scottish Enterprise: medical device, anaesthesia  University of Bath: human and animal vaccine technology Due diligence  Apposite (Anaphore), Finance Wales (ADCB) & Wellcome (Kymab) Strategic advice  ThermoFisher, Smith & Nephew, Wellcome Genome Campus Management, mentoring & coaching  ProteinLogic, Scottish Enterprise & Theryte Portfolio review  Bloomsbury Bioseed Fund

Case Study: Psynova Neurotech Biomarkers for psychiatric disorders –Potential applications in diagnostics, drug discovery and development Ithaka role –Development of commercial strategy, business plan & securing of finance in 2007 –Paul Rodgers: chairman from 2007 to 2012 Results –University spin-out company 2007 –> £8M investment & grant funding –First diagnostic product launched in 2010 –Commercial deal with Roche Pharmaceuticals Dec 2009 –Acquired by Myriad Genetics 2011

Why Work with Ithaka? Personal experience –Technology commercialisation –New ventures –Fund raising –Growth through strategic partnerships –Across the life science spectrum Multi-disciplinary team approach Unique network of contacts Support tailored to meet the client’s needs